How Doceree is Leveraging its Point-of-Care Marketing
August 29th 2025Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.
How AI Could Evolve Programmatic Marketing in Physician-Only Platforms
August 28th 2025Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.
Why Court Battles Could Alter the Path of Emergency Use Authorizations for Vaccines
August 20th 2025Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA decision-making and reshape how future emergency use authorizations are granted.
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 19th 2025Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage challenges.
The Challenges and Advantages of US Healthcare in a Worldwide Perspective
August 18th 2025Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical technology while facing challenges such as rising costs, lack of universal coverage, and health outcomes that lag behind other high-income nations.
Understanding the Impact of Health Economics on Cost Effectiveness and Patient Outcomes
August 14th 2025Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs globally.
Magellan AI Identifies and Optimizes Molecules Beyond the Public Domain
August 6th 2025Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.
What the Emrelis Approval Means for Pharma and Biotech ADC Strategies
July 24th 2025Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic paths for pharma and biotech in the evolving precision oncology landscape.